Remepy is Pioneering Hybrid Drugs™.
Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.
Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms
Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
Company Details
- Employees
- 52
- Founded
- -
- Address
- New York, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.remepy.com/
- Keywords
- Pharma, Biotech, Digital Health, Software, mobile apps, immunology, drug development, oncology, Neurology.
- HQ
- New York, NY
Remepy Questions
Remepy's website is https://www.remepy.com/
Remepy's LinkedIn profile is https://www.linkedin.com/company/remepy
Remepy has
52 employees.
View email and phone details for 52
employees at Remepy.
Remepy's industry is
Biotechnology Research
Remepy's top competitors are
Healthee,
Grip Security,
Sedric,
Identifai Genetics,
Bria Ai,
Phasev,
Guidde,
4m Analytics,
Kaltura,
Darrow Ai.
Remepy's categories are Biotechnology Research
Remepy's founding year is 2022
